In DN, the target BP is <130/80 mmHg, with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) preferred for their renoprotective effects (Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT) trials) [118]. Here, ACE is linked to liver dysplastic nodule.